PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer

Frederik A. Verburg*, David Pfister, Natascha I. Drude, Felix M. Mottaghy, Florian F. Behrendt

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Translated title of the contributionPSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer
Original languageGerman
Pages (from-to)225-232
Number of pages8
JournalNuklearmedizin
Volume56
Issue number6
DOIs
Publication statusPublished - 2017

Keywords

  • PSA
  • PSA doubling time
  • Gleason score
  • prostate cancer
  • [Ga-68]PSMA-HBED-CC PET/CT
  • MEMBRANE ANTIGEN-EXPRESSION
  • DIFFERENTIATED THYROID-CANCER
  • GA-68-PSMA LIGAND PET/CT
  • INTRAEPITHELIAL NEOPLASIA
  • BIOCHEMICAL RECURRENCE
  • PSMA EXPRESSION
  • CELIAC GANGLIA
  • PRIMARY TUMOR
  • ADENOCARCINOMA
  • REMISSION

Cite this